EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Cinclus Pharma secured funding to support its preparations for a phase 2 trial of a potassium competitive acid blocker in erosive gastroesophageal reflux disease. Statement 

> Mereo BioPharma completed its reverse merger with OncoMed Pharmaceuticals and began trading on Nasdaq. The developments extend Mereo’s cash runway out to the middle of next year. Release I More

> The FDA granted orphan drug status to Autolus Therapeutics’ CD19-CD22 cell therapy AUTO3 in the treatment of acute lymphoblastic leukemia. Statement 

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

> Marinomed Biotech posted top-line data from a phase 3 clinical trial of allergic rhinitis nasal spray Budesolv. The trial found Budesolv had comparable effects to another budesonide product but at a lower dose. Release 

> Cytura Therapeutics raised seed funding to develop drugs targeting genomic instability in cancer.  A syndicate led by Thuja Capital Healthcare put up the money. Statement 

> Oxurion completed enrollment in a phase 1 trial of plasma kallikrein inhibitor THR-149 ahead of schedule. The milestone positions Oxurion to share initial data on the diabetic macular edema prospect early in the third quarter. Release 

Suggested Articles

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.

Annexon Biosciences and AlloVir are seeking a $100 million IPO apiece in a buoyant market that shows no signs of slowing down.

Cellectis said the multiple myeloma patient suffered a cardiac arrest after receiving the highest dose of the anti-CS1 allogeneic CAR-T.